Compare Crispr Therapeutics AG (CRSP) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs KB Financial Group, Inc. — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while KB Financial Group, Inc. trades at $122.87 (market cap $41.53B). The key difference: KB Financial Group, Inc. is far larger — about 8.4× Crispr Therapeutics AG's market cap, and KB Financial Group, Inc. pays a 2.6% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | KB | |
|---|---|---|
Market Cap | $4.97B | $41.53B |
Sector | Health | Financials |
52-Week High | $76.78 | $123.25 |
52-Week Low | $44.34 | $77.50 |
Enterprise Value | $3.32B | — |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
KB Financial Group (KB) trades at $123.25, up 0.05% with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, 27.82% net income margin, and 27.47% profit margin in 2025. Recent news highlights expansion into non-banking segments and dividend potential. Revenue grew to $21.23T in 2025, with net income reaching $5.83T.
The outlook remains positive with earnings growth and diversification driving upside, though technical oscillators signal overbought conditions. Risks include volatile cash flows and competitive pressures. Analyst consensus is mixed with 33% buy ratings. The stock presents value with a P/E of 11.84 but requires monitoring of execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
